Goldman Sachs
RVMD icon

Goldman Sachs’s Revolution Medicines RVMD Stock Holding History

Goldman Sachs’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,000
Closed -$1.67M – 6922
2025
Q4 		$1.67M Hold
21,000
– – ﹤0.01% 4747
2025
Q3 		$981K Buy
+21,000
New +$822K ﹤0.01% 5036

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Goldman Sachs's RVMD Position: Q2 2026 in Review

Goldman Sachs reduced its Revolution Medicines (RVMD) stake by 2.4% in Q2 2026, selling an estimated $7.65M and leaving 2,133,101 shares worth $399M. The position accounts for 0.03% of the portfolio, ranked #474.

Goldman Sachs first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Goldman Sachs held 2,133,101 shares of Revolution Medicines worth $399M as of Q2 2026.
  • Goldman Sachs sold 52,399 Revolution Medicines shares in Q2 2026, an estimated $7.65M.
  • Revolution Medicines made up 0.03% of Goldman Sachs's portfolio in Q2 2026, its #474 holding.
  • Goldman Sachs first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.